2018
DOI: 10.1097/j.pain.0000000000001370
|View full text |Cite
|
Sign up to set email alerts
|

The opioid receptor mu 1 (OPRM1) rs1799971 and catechol-O-methyltransferase (COMT) rs4680 as genetic markers for placebo analgesia

Abstract: The placebo effect is considered the core example of mind-body interactions. However, individual differences produce large placebo response variability in both healthy volunteers and patients. The placebo response in pain, placebo analgesia, may be dependent on both the opioid system and the dopaminergic system. Previous studies suggest that genetic variability affects the function of these 2 systems. The aim of this study was therefore to address the interaction between the single nucleotide polymorphisms opi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
21
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
6
2
2

Relationship

1
9

Authors

Journals

citations
Cited by 25 publications
(21 citation statements)
references
References 44 publications
0
21
0
Order By: Relevance
“…Linear mixed models (LMM) were used to analyze the repeated data for pain intensity and pain thresholds. LMM's were chosen because these analyses are suitable for analyzing data with unequal group sizes, handle missing data without losing power in the analyses compared with standard general linear models, and allows for combinations of both fixed and random effects (Aslaksen et al, 2018).…”
Section: Discussionmentioning
confidence: 99%
“…Linear mixed models (LMM) were used to analyze the repeated data for pain intensity and pain thresholds. LMM's were chosen because these analyses are suitable for analyzing data with unequal group sizes, handle missing data without losing power in the analyses compared with standard general linear models, and allows for combinations of both fixed and random effects (Aslaksen et al, 2018).…”
Section: Discussionmentioning
confidence: 99%
“…Neurophysiological study indicated that genetic variations in neurotransmitter pathways mediating placebo effects provided the possibility of identifying placebo responders through genetic screening [43]. Based on recent studies, catechol-o-methyltransferase (COMT) and opioid receptor (OPRM1) participated in mediating the regulation of psychological process and pain process [44][45][46][47]. These genes will be selected as candidate genes for objectively assessing and predicting the specific and nonspecific effects of acupuncture, estimating correlations among gene polymorphisms, psychological factors, and brain activity.…”
Section: Oxytocin and Genetics Evaluationmentioning
confidence: 99%
“…Neurophysiological study indicated that genetic variations in neurotransmitter pathways mediating placebo effects provided the possibility of identifying placebo responders through genetic screening [44]. Based on recent studies, catechol-o-methyltransferase (COMT) and opioid receptor (OPRM1) participated in mediating the regulation of psychological process and pain process [45][46][47][48]. These genes will be selected as candidate genes for objectively assessing and predicting the speci c and nonspeci c effects of acupuncture, estimating correlations among gene polymorphisms, psychological factors and brain activity.…”
Section: Oxytocin and Genetics Evaluationmentioning
confidence: 99%